Respiratory Fluoroquinolones for Respiratory Tract Infections
Primary Recommendations by Clinical Setting
- The American Academy of Pediatrics recommends levofloxacin (500-750 mg once daily) and moxifloxacin (400 mg once daily) for respiratory tract infections, while ciprofloxacin should NOT be used due to inadequate pneumococcal coverage 1, 2, 3
- For outpatients with comorbidities or recent antibiotic exposure, the Infectious Diseases Society of America recommends levofloxacin 750 mg once daily for 5 days OR 500 mg once daily for 7-14 days 4
- For hospitalized patients, the Infectious Diseases Society of America recommends levofloxacin 750 mg once daily as monotherapy or moxifloxacin 400 mg once daily as monotherapy 4
- For ICU patients with severe CAP, the Infectious Diseases Society of America recommends β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either levofloxacin 750 mg daily OR azithromycin 4
Antimicrobial Coverage
- The American Academy of Pediatrics states that all respiratory fluoroquinolones demonstrate activity against S. pneumoniae, H. influenzae, M. catarrhalis, and atypical pathogens: M. pneumoniae, C. pneumoniae, L. pneumophila 1, 2, 5
- Resistance surveillance data show virtually no levofloxacin resistance in children younger than 2 years and overall S. pneumoniae resistance to levofloxacin remains <1% in the US 7
Critical Contraindications and Warnings
- The FDA requires boxed warnings for tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis 7
- Advanced age increases risk for severe tendon disorders, further increased by concomitant corticosteroid therapy 7
Common Pitfalls to Avoid
- The American College of Clinical Pharmacy recommends avoiding ciprofloxacin for community-acquired pneumonia due to inadequate pneumococcal coverage and treatment failures 1, 6, 3
- The Infectious Diseases Society of America recommends using 750 mg daily of levofloxacin for severe pneumococcal infections to overcome resistance mechanisms 2, 6